{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:33:02Z","timestamp":1769045582189,"version":"3.49.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Amyloid A (AA) amyloidosis involving the gastrointestinal (GI) tract is a rare but potentially life-threatening complication of chronic inflammatory rheumatic diseases. Although typically associated with long-standing rheumatoid arthritis (RA), it is rarely reported in the context of RA\u2013peripheral spondyloarthritis (pSpA) overlap syndrome. We report a rare case of early-onset GI-predominant AA amyloidosis without renal involvement in a patient with overlapping RA and HLA-B27\u2013positive pSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 52-year-old male presented with progressive arthritis involving the knees, ankles, and toes. Despite RA treatment, inflammatory markers remained elevated. He later developed anterior uveitis and gastrointestinal symptoms including abdominal pain and diarrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>He fulfilled classification criteria for both RA and pSpA. Endoscopic biopsy revealed amyloid A deposits in the stomach and duodenum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Intravenous tocilizumab was initiated every 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 2 months of tocilizumab treatment, GI symptoms markedly improved, inflammatory markers and serum albumin normalized, and imaging demonstrated resolution of bowel wall edema. Serum amyloid A levels also markedly decreased to within the normal range. The patient achieved sustained remission of articular and gastrointestinal manifestations at 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case illustrates early GI-dominant AA amyloidosis without renal involvement in RA\u2013pSpA overlap. The coexistence of intense inflammatory responses and mucosal immune activation may predispose the GI tract to early amyloid deposition, emphasizing the need for active surveillance and early endoscopic evaluation in patients presenting with unexplained GI symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046291","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:00:27Z","timestamp":1764597627000},"page":"e46291","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early-onset gastrointestinal amyloid A amyloidosis without renal involvement in a patient with RA\u2013pSpA overlap: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-5613","authenticated-orcid":false,"given":"Hyeok Chan","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Dankook University College of Medicine, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260121","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis.","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20260121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.2012.068155","article-title":"Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.","volume":"98","author":"Cowan","year":"2013","journal-title":"Haematologica"},{"key":"R3-20260121","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00296-012-2646-3","article-title":"Secondary amyloidosis in ankylosing spondylitis.","volume":"33","author":"D\u00f6nmez","year":"2013","journal-title":"Rheumatol Int"},{"key":"R4-20260121","doi-asserted-by":"crossref","first-page":"661101","DOI":"10.3389\/fmed.2021.661101","article-title":"Successful treatment of AA amyloidosis in ankylosing spondylitis using tocilizumab: report of two cases and review of the literature.","volume":"8","author":"Eriksson","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R5-20260121","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative.","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R6-20260121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R7-20260121","first-page":"850","article-title":"Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments.","volume":"29","author":"Nakamura","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"R8-20260121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5114\/reum.2015.55832","article-title":"Coexistence of rheumatoid arthritis and ankylosing spondylitis.","volume":"53","author":"Barczy\u0144ska","year":"2015","journal-title":"Reumatologia"},{"key":"R9-20260121","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/rheumatology\/40.7.821","article-title":"Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide.","volume":"40","author":"Chevrel","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20260121","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","article-title":"Role of HLA\u2011B27 in the pathogenesis of ankylosing spondylitis (review).","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"key":"R11-20260121","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management.","volume":"6","author":"de As\u00faa","year":"2014","journal-title":"Clin Epidemiol"},{"key":"R12-20260121","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.berh.2018.08.012","article-title":"Subclinical gut inflammation in spondyloarthritis.","volume":"31","author":"Rizzo","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R13-20260121","first-page":"e1228","article-title":"Gastrointestinal amyloidosis: review of the literature.","volume":"9","author":"Rowe","year":"2017","journal-title":"Cureus"},{"key":"R14-20260121","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nefroe.2022.02.003","article-title":"Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis.","volume":"42","author":"Almenara-Tejedoras","year":"2022","journal-title":"Nefrolog\u00eda (Engl Ed)"},{"key":"R15-20260121","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40620-023-01845-z","article-title":"Tocilizumab (anti-IL-6) treatment for AA renal amyloidosis in a patient with advanced chronic kidney disease: a case report.","volume":"37","author":"Sene\u0161chall","year":"2024","journal-title":"J Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:02:54Z","timestamp":1768993374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":15,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046291","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}